Cases & Deals

  • Home
  • Practices
  • LeaderMed Health Group Limited enters into joint venture and licensing agreement with OPKO Health to develop and commercialize innovative drugs in Asian countries

Share

LeaderMed Health Group Limited enters into joint venture and licensing agreement with OPKO Health to develop and commercialize innovative drugs in Asian countries

September 2021

Client(s) Leadermed Health Group Limited

Jones Day represented LeaderMed Health Group Limited in the formation of a joint venture and exclusive license agreement with OPKO Health, Inc. ("OPKO") to develop, manufacture, and commercialize two of OPKO's clinical stage, long-acting drug products, Oxyntomodulin and Factor VIIa-CTP, in Greater China and eight other Asian territories.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.